Tag Archives: IPO

Prosensa’s IPO and the Value of the BIO Investor Forum

Hans Schikan

Prosensa (NASDAQ: RNA) is a Dutch biotechnology company engaged in the discovery and development of RNA-modulating therapeutics for the treatment of genetic disorders. Our primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington’s disease. We completed an IPO onto NASDAQ in June of this year. Prior to last year’s BIO Investor Forum in San Francisco, we were still in the very Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

JOBS Act Provides Innovators with Capital Boost

jobs-act-article

Despite all the talk of gridlock and polarization in Washington these days, successful, bipartisan pieces of legislation are not a thing of the past. One of them is the Jumpstart Our Business Startups (JOBS) Act, which makes it easier for emerging growth companies to raise capital by going public. The JOBS Act provides qualifying companies with a five year “on-ramp” period to comply with some of the regulatory requirements involved when making the transition from Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , ,

The Return of the Biotech IPO

Graph

It isn’t just the volume of IPOs this summer that makes this window a victory for hibernating private biotechs and their VC backers, it’s the details of the offerings in terms of price, performance, and type of biotech making the leap onto the public stage. For the last five years we have not seen average offering prices land above expectations, but 2013 is breaking that trend. Price performance is also impressive, with a number of Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,

BIO-Europe Spring Opening Remarks

Chart

BIO’s own David Thomas, Director of Industry Research, delivered opening remarks at the BIO-Europe Spring conference in Barcelona yesterday. His slides provide a snapshot of the biotech industry’s performance and highlight emerging trends in venture exits: IPOs and M&A. Takeaways from his talk include breakouts on multiple fronts for the industry: FDA approvals at highs not seen since the 1990s Orphan designation approvals at all-time highs IPOs starting to show signs of life in 2012 Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

The Good, the Bad, and the Ugly for Biotech IPOs

2012-11-12-Technology-vs-HC-IPOs-btn

The troubles in the biotech IPO market are complicated to explain to industry outsiders. They read about new biotechs debuting on the public market, but also hear bankers, VCs, and CEOs complaining about how the IPO window never really opened after 2008. The reality is that we are seeing positive developments and negative trends simultaneously. On the bright side, the cumulative number of IPOs is holding up. The recent pace of biotech IPOs mimics what Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,